Amcinonide vs. betamethasone dipropionate ointments in the treatment of psoriasis

A. C. Huntley, Roslyn Rivkah Isseroff

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A randomized, double-blind study compared the efficacy and safety of amcinonide and betamethasone dipropionate ointments, applied twice daily for two weeks, in the treatment of patients with moderate to severe psoriasis. Thirty-four patients were enrolled; thirty patients had had psoriasis for more than one year, and in the majority of patients, it was stable or slowly exacerbating. Significant improvement from baseline was observed with both ointments at weeks 1 and 2. The two drugs showed comparable cosmetic acceptability. Adverse cutaneous symptoms experienced were burning (both groups), itching (amcinonide), and stinging (betamethasone); no serious adverse effects were reported.

Original languageEnglish (US)
Pages (from-to)489-492
Number of pages4
JournalCutis
Volume35
Issue number5
StatePublished - 1985

Fingerprint

Ointments
Psoriasis
Betamethasone
Therapeutics
Pruritus
Double-Blind Method
Cosmetics
Safety
Skin
betamethasone-17,21-dipropionate
amcinonide
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Dermatology
  • Immunology and Allergy

Cite this

Amcinonide vs. betamethasone dipropionate ointments in the treatment of psoriasis. / Huntley, A. C.; Isseroff, Roslyn Rivkah.

In: Cutis, Vol. 35, No. 5, 1985, p. 489-492.

Research output: Contribution to journalArticle

@article{844974d26fd24b6b8e6e0d8651341429,
title = "Amcinonide vs. betamethasone dipropionate ointments in the treatment of psoriasis",
abstract = "A randomized, double-blind study compared the efficacy and safety of amcinonide and betamethasone dipropionate ointments, applied twice daily for two weeks, in the treatment of patients with moderate to severe psoriasis. Thirty-four patients were enrolled; thirty patients had had psoriasis for more than one year, and in the majority of patients, it was stable or slowly exacerbating. Significant improvement from baseline was observed with both ointments at weeks 1 and 2. The two drugs showed comparable cosmetic acceptability. Adverse cutaneous symptoms experienced were burning (both groups), itching (amcinonide), and stinging (betamethasone); no serious adverse effects were reported.",
author = "Huntley, {A. C.} and Isseroff, {Roslyn Rivkah}",
year = "1985",
language = "English (US)",
volume = "35",
pages = "489--492",
journal = "Cutis",
issn = "0011-4162",
publisher = "Quadrant Healthcom Inc.",
number = "5",

}

TY - JOUR

T1 - Amcinonide vs. betamethasone dipropionate ointments in the treatment of psoriasis

AU - Huntley, A. C.

AU - Isseroff, Roslyn Rivkah

PY - 1985

Y1 - 1985

N2 - A randomized, double-blind study compared the efficacy and safety of amcinonide and betamethasone dipropionate ointments, applied twice daily for two weeks, in the treatment of patients with moderate to severe psoriasis. Thirty-four patients were enrolled; thirty patients had had psoriasis for more than one year, and in the majority of patients, it was stable or slowly exacerbating. Significant improvement from baseline was observed with both ointments at weeks 1 and 2. The two drugs showed comparable cosmetic acceptability. Adverse cutaneous symptoms experienced were burning (both groups), itching (amcinonide), and stinging (betamethasone); no serious adverse effects were reported.

AB - A randomized, double-blind study compared the efficacy and safety of amcinonide and betamethasone dipropionate ointments, applied twice daily for two weeks, in the treatment of patients with moderate to severe psoriasis. Thirty-four patients were enrolled; thirty patients had had psoriasis for more than one year, and in the majority of patients, it was stable or slowly exacerbating. Significant improvement from baseline was observed with both ointments at weeks 1 and 2. The two drugs showed comparable cosmetic acceptability. Adverse cutaneous symptoms experienced were burning (both groups), itching (amcinonide), and stinging (betamethasone); no serious adverse effects were reported.

UR - http://www.scopus.com/inward/record.url?scp=0021808586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021808586&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 489

EP - 492

JO - Cutis

JF - Cutis

SN - 0011-4162

IS - 5

ER -